Curcumin differentially sensitizes malignant glioma cells to TRAIL/Apo2L-mediated apoptosis through activation of procaspases and release of cytochrome c from mitochondria

Journal of Experimental Therapeutics and Oncology

Volumn 5, Issue 1, 2005, Pages 39-48

  Gao, Xiaohua ^a   Deeb, Dorrah ^a   Jiang, Hao ^a   Liu, Yong B ^a   Dulchavsky, Scott A ^a   Gautam, Subhash C ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Apoptosis; Caspases; Curcumin; Cytochrome c; Glioma; TRAIL

Indexed keywords

CURCUMIN; CYTOCHROME C; POLYPHENOL DERIVATIVE; PROCASPASE 3; PROCASPASE 8; PROCASPASE 9; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN MITOCHONDRION; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CELL CYCLE G1 PHASE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CURCUMA LONGA; DIPLOIDY; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME RELEASE; GLIOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SENSITIZATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CASPASE 3; CASPASE 8; CASPASE 9; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; CYTOCHROMES C; ENZYME ACTIVATION; GLIOMA; HUMANS; INDICATORS AND REAGENTS; L-LACTATE DEHYDROGENASE; MEMBRANE GLYCOPROTEINS; MITOCHONDRIA; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 23044494635     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Hosli P, Sappino A, de Tribolet N and Dietrich P. Ann. Oncol. 9: 589-600, 1998.
2. DeAngelis, LM, Burger PC, Green SB, and Caironcross JG. Malignant glioma: who benefits from adjuvant chemotherapy. Ann. Neurol 44: 691-695, 1998.
3. Fine HA, Dear KB, Loeffler, JS, Black, PM, and Canellos, GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Caner 71: 2585-2597, 1993.
4. Kim TS, Halliday AL, Hedley-Whyte ET, Convey K. Correlates of survival and the Dumas-Duport grading system for astrocytomas. J Neurosurg 74: 27-37, 1991.
5. Shapiro WR, Green SB, Burger PC, Maheley MS Jr, Selker RG, VanGilder JC, Robertson JT, Ransohoff J, Mealey J Jr, Strike TA et al. Randomized trials of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant gliomas. J Neurosurg 71: 1-9, 1989.
6. Arceci R.J. Mechanism of resistance to therapy and tumor survival. Curr Opin Hematol 2: 268-274, 1995.
7. Denmeade, S.R., Lin, X.S., and Isaacs, J.T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28: 251-265, 1996.
8. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 73: 2013-2026, 1994.
9. Rieger J, Naumann U, Glaser T, Ashkenazi A., and Weller M. APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Letters 427: 124-128, 1998.
10. Knight MJ, Riffkin CD, Muscat AM, Ashley DM, and Hawkins CJ. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene 20: 5789-5798, 2001.
11. Pollack IF, Erff M., and Ashkenazi A. Direct stimulation of apoptotic signaling by soluble apo2L/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 7: 1362-1369, 2001.
12. Mizutani Y, Bonavida B. Overcoming CDDP resistance of human ovarian tumor cells by combination treatment with CDDP and TNF-a. Cancer 72: 809-818, 1993.
13. Mizutani Y, Okada Y, Fukomoto M, Bonavida B, and Yoshida O. Doxorubicin sensitizes human bladder cell carcinoma cells to Fas-mediated cytotoxicity. Cancer 79: 1180-1189, 1997.
14. Rohn TA, Wagenknecht B, Roth W, Naumann U, Gulbins E, Krammer PH, Walczak H, and Weller M. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene 20: 4128-4137, 2001.
15. Wiley, S.R., Schooley, K., Smolak, P.J., Din, W.S., Cuang, C-P., Nicholl, J.K., Sutherland, G.R., Smith, C.A., and Goodwin, R.G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.
16. Pitti, R.M., Marsters, S.A., Ruppert, S., Donahue, C.J., Moore, A., and Ashkenazi, A. Induction of apoptosis by Apo-2 ligand, a new member of the family of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690, 1996.
17. Walczak, H., Miller, R.E., Ariail, K., Gliniak, B., Griffith, T.S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R.G., Rauch, C.T., Schuh, J.C.L., and Lynch, D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
18. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence, DA, Marsters SA, Blakie C, Chan L, McMurtrey AE, Hebert A, Deforge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, and Schwall RH. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 152-162, 1999.
19. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH, and Runkel L. Involvement of CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182: 1223-1230, 1995.
20. + organs. Blood 95: 2111-2117, 2000.
21. Grunfeld C, and Palladino MA. Tumor necrosis factor: immunologic, antitumor, metabolic, and cardiovascular activities. Adv Intern Med 35: 45-74, 1990.
22. Jo M Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6: 564-567, 2000.
23. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH, et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 60: 553-559, 2000.
24. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatotoxicity of recombinant Apo2L/TRAIL versions. Nat Med 7: 383-385, 2001.
25. Huang MT, Lysz T, Ferraro T, Abidi TF, Laskin JD, and Conney AH. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 51: 813-819, 1991.
26. Ruby AJ, Kuttan G, Babu D, Rajasekharan KN, and Kuttan R. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 94: 79-83, 1995.
27. Huang MT, Newmark HL, and Frenkel K. Inhibitory effects of curcumin on tumorigenesis in mice. J Cell Biochem 27: 26-34, 1997.
28. Huang MT, Lou YR, Ma W, Newmark HL, Reuhl KR. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res 54: 5841-5847, 1994.
29. Rao CV, Rivenson A, Simi B, Reddy BS. Chemoprevention of colon cancer by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55: 259-266, 1995.
30. Chen HW, Huang HC. Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Brit J Pharmacol 124: 1029-1040, 1998.
31. Anto RJ, Mukhopadadhyay A, Denning K, and Aggarwal BB. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xL. Carcinogenesis 23: 143-150, 2002.
32. Mukhopadhyaya A, Bueso-Ramos C, Chatterjee D, Pantazis P, and Aggarwal B. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20: 597-7609, 2001.
33. Gautam SC, Xu YX, Pindolia KR, Janakiraman N, and Chapman RA. Nonselective inhibition of proliferation of transformed and nontransformed cells by the anticancer agent curcumin (diferuloylmethane). Biochem Pharmacol 55: 1333-1337, 1998.
34. Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, Chapman RA, and Gautam SC. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Therapeutics 2: 95-103, 20023.
35. Deeb D, Jiang H, Gao X, Hafner MS, Wong H, Divine G, Chapman RA, Dulchavsky SA, and Gautam SC. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-KB through suppression of IKB α phosphorylation. Mol Cancer Therapeutics 3: 803-812, 2004.
36. Willett WC. Diet and health: what should we eat? Science 264: 532-537, 1994.
37. Constant J. Alcohol, ischemic heart disease, and French paradox. Coron Artery Dis 8: 645-649, 1997.
38. Gautam SC, Xu YX, Janakiraman N, and Chapman RA. Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging. Bone Marrow Transplant 25: 639-645, 2000.
39. Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN. Pretreatment with paclitaxel enhances Apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 61: 759-763, 2001.
40. Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, and Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer 38: 177-183, 2002.
41. Munshi A, McDonnell TJ, and Meyn RE. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 50: 46-52, 2002.
42. Sun S-Y, Yue P, Hong WK, and Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6[3-(1-adamantyl)-4-hydroxyphenyl]-2 napthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res 60: 7149-7155, 2000.
43. Ashkenazi A, and Dixit VM. Death receptors: Signaling and modulation. Science 281: 1305-1308, 1998.
44. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 10: 559-563, 1998.
45. Sun X-M, MacFarlane M, Zhuang J, Wolf BB, Green DR, and Cohen GM. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 274: 5053-5060, 1999.
46. Li H, Zhu H, Xu CJ, and Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501, 1998.
47. Luo X, Budihardjo I, Zou H, Slaughter C, and Wang X. Bid, aBcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490, 1998.
48. Weaver KD, Yeyeodu S, Cusack JC Jr, Baldwin AS Jr, Ewend MG. Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 61: 187-96, 2003.
49. Cusack JC Jr. Overcoming antiapoptotic responses to promote chemosensitivity in metastatic colorectal cancer to the liver. Ann Surg Oncol 10: 852-62, 2003.